MSF warns about lack of access to antiretroviral treatment in DRC, urges government, donor action

"Eighty-six percent of HIV-positive people in the Democratic Republic of Congo [DRC] have no access to antiretrovirals, medical charity Doctors Without Borders said Wednesday," calling the "conditions of access to care for people living with HIV/AIDS ... catastrophic," Agence France-Presse reports (1/25). Approximately 15,000 people living with HIV in the DRC "likely will die waiting for lifesaving drugs in the next three years," the organization, also known as Medecins Sans Frontieres (MSF), said, the Associated Press reports.

A statement from the organization "called for Congo's government to meet its commitment to provide free treatment to people living with HIV and AIDS, and for donors to immediately mobilize resources 'to ensure that patients waiting for ARV treatment are not condemned to die,'" according to the AP. Of an estimated 350,000 people in need of antiretroviral treatment, only 44,000 are receiving therapy, the AP notes (Mwanamilongo, 1/25).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New insights into the mechanisms of efavirenz-induced neurotoxicity